Introduction
Methods
Data source
Patient selection criteria
Study design
Study variables
Patient characteristics
Treatment patterns
Outcomes
Statistical analysis
Results
Study sample
N = 242 | |
---|---|
Age (continuous), years | |
Mean (SD) | 52.5 (18.0) |
Gender, female, n (%) | 123 (50.8) |
Insurance type, n (%) | |
Commercial | 70 (28.9) |
Medicaid | 43 (17.8) |
Medicare | 53 (21.9) |
Commercial/Medicaid | 8 (3.3) |
Commercial/Medicare | 19 (7.9) |
Medicare/Medicaid | 8 (3.3) |
Commercial/Medicare/Medicaid | 2 (0.8) |
Invalid, missing, unknown, other | 16 (6.6) |
Uninsured | 23 (9.5) |
Race, n (%) | |
Asian | 3 (1.2) |
Black or African American | 36 (14.9) |
White or Caucasian | 186 (76.9) |
Unknown/other | 17 (7.0) |
Ethnicity, n (%) | |
Hispanic, Latino, or Spanish | 24 (9.9) |
Not Hispanic, Latino, or Spanish | 210 (86.8) |
Unknown/other | 8 (3.3) |
Charlson Comorbidity Index score | |
Mean (SD) | 2.31 (1.97) |
Underlying qualifying conditions,* n (%) | |
Hepatitis C | 108 (44.6) |
SLE | 44 (18.2) |
CLL or SLL | 37 (15.3) |
APS | 26 (10.7) |
Evans syndrome | 19 (7.9) |
CVID | 12 (5.0) |
HIV | 12 (5.0) |
Selective IgA deficiency | 7 (2.9) |
Autoimmune lymphoproliferative disorder | 2 (0.8) |
Treatment patterns
N = 242 | |
---|---|
Time from sITP diagnosis to eltrombopag treatment, months, mean (SD) | 1.1 (4.2) |
Duration of eltrombopag treatment, months, mean (SD) | 6.1 (6.9) |
Patients who received eltrombopag monotherapy, n (%) | 202 (83.5) |
Patients who received eltrombopag in combination with additional ITP therapy, n (%) | 40 (16.5) |
Reason for the end of observed eltrombopag treatment period, n (%) | |
Discontinuation | 146 (60.3) |
Add-on or switch | 45 (18.6) |
End of activity in EHR database or end of the study period | 47 (19.4) |
Death | 4 (1.7) |
Individuals who discontinued* eltrombopag treatment, and entered a treatment-free period** during available follow-up, n (%) | 105 (43.4) |
Observed length of treatment-free period, months, mean (SD) | 3.3 (3.4) |
Individuals with another line of therapy after eltrombopag, n (%) | 84 (34.7) |
Time from end of eltrombopag treatment to start of subsequent line, months, mean (SD) | 5.7 (10.3) |
Platelet response
Thrombotic and bleeding events
6-month baseline period before eltrombopag | Eltrombopag treatment period*‡ | p-values | |
---|---|---|---|
Thrombotic events, mean (SD) per patient | 0.16 (0.46) | 0.08 (0.31) | 0.027 |
Patients with specific events, n (%) | |||
Thrombotic stroke | 6 (2.48) | 4 (1.65) | 0.528 |
Transient ischemic attack | 4 (1.65) | 2 (0.83) | 0.416 |
Myocardial infarction | 4 (1.65) | 3 (1.24) | 0.706 |
Deep vein thrombosis | 15 (6.20) | 9 (3.72) | 0.222 |
Pulmonary embolism | 9 (3.72) | 1 (0.41) | 0.012 |
Bleeding and hemorrhage events, n (%) of patients with ≥ 1 event | 78 (32.2) | 67 (27.7) | 0.628 |